Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.53 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.51 |
| ▸ | CLK2 | P49760 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440513 | 1.00 | MAPK1 (0.55) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| SCHEMBL29491224 | 0.85 | NOS1 (0.53) | NOS1MEN1KMT2AMAPTMETAP2 | |
| SCHEMBL879376 | 0.85 | NOS1 (0.53) | NOS1MEN1KMT2AMAPTMETAP2 | |
| SCHEMBL8666610 | 0.84 | NOS1 (0.57) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| SCHEMBL764032 | 0.81 | CDC7 (0.55) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| SCHEMBL8805964 | 0.81 | MAPK1 (0.54) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| SCHEMBL6726541 | 0.81 | NOS1 (0.58) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| SCHEMBL264211 | 0.81 | ROCK2 (0.58) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| SCHEMBL29728756 | 0.81 | ROCK2 (0.58) | MAPK1ROCK2NOS1ROCK1MEN1 | |
| Bromide SCHEMBL3866479 | 0.79 | NOS1 (0.56) | MAPK1ROCK2NOS1ROCK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11447465-B2 | Pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | MAPK1 353/4885ROCK2 1025/4885NOS1 2864/4885 |
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | MAPK1 380/4885ROCK2 3539/4885NOS1 807/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MAPK1 380/4885ROCK2 3539/4885NOS1 807/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MAPK1 27/4885ROCK2 2/4885NOS1 131/4885 |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | MAPK1 332/4885ROCK2 1934/4885NOS1 2432/4885 |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | MAPK1 2538/4885ROCK2 4240/4885NOS1 4324/4885 |
| US-11447465-B2 | Pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | MAPK1 380/4885ROCK2 3539/4885NOS1 807/4885 |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | MAPK1 2538/4885ROCK2 4240/4885NOS1 4324/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | MAPK1 2600/4885ROCK2 3281/4885NOS1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.